Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

被引：0

作者：

Ma, W. ^{[1
]}

Gong, J. ^{[1
]}

Shan, J. ^{[2
]}

Lewis, D. ^{[2
]}

Xiao, W. ^{[3
]}

Hung, J. ^{[4
]}

Moore, E. H. ^{[5
]}

Zhang, Y. ^{[6
]}

Mans, N. Z. ^{[7
]}

Welborn, J. ^{[5
]}

Lam, K. S. ^{[3
]}

Li, T. ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA

[2] Albert Einstein Coll Med, Dept Genet, New York, NY USA

[3] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA

[4] Sierra Nevada Med Grp, Grass Valley, CA USA

[5] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA

[6] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA

[7] Univ Calif Davis, Hereditary Canc Program, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

osimertinib; lung cancer; Germline EGFR T790M;

D O I：

10.1016/j.jtho.2017.09.590

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 15.08

引用

页码：S1863 / S1864

页数：2

共 50 条

[41] The different path of T790M-positive EGFR-mutant lung cancer
Yoon, Shinkyo
Choi, Chang Min
Lee, Jae Cheol
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
[42] De novo EGFR T790M mutation in lung cancer patients harboring sensitive EGFR mutations
Lee, Youngjoo
Lee, Geon Kook
Lee, Yeon-Su
Zhang, Wenji
CANCER RESEARCH, 2014, 74 (19)
[43] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
Tseng, Jeng-Sen
Su, Kang-Yi
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Chen, Hsuan-Yu
Tsai, Chi-Ren
Yu, Sung-Liang
Chang, Gee-Chen
ONCOTARGET, 2016, 7 (30) : 48059 - 48069
[44] In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M
Nishii, Kazuya
Ohashi, Kadoaki
Makimoto, Go
Higo, Hisao
Ninomiya, Kiichiro
Kayatani, Hiroe
Ninomiya, Takashi
Kubo, Toshio
Rai, Kammei
Ichihara, Eiki
Hotta, Katsuyuki
Tabata, Masahiro
Kiura, Katsuyuki
CANCER RESEARCH, 2018, 78 (13)
[45] EGFR T790M Mutation A Double Role in Lung Cancer Cell Survival?
Suda, Kenichi
Onozato, Ryoichi
Yatabe, Yasushi
Mitsudomi, Tetsuya
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 1 - 4
[46] Evaluation of the relationship between clinicopathological features at diagnosis and acquisition of T790M resistance mutation in patients with EGFR-mutant metastatic lung cancer
Dogan, I.
Khanmamadov, N.
Paksoy, N.
Vatansever, S.
Saip, P.
Aydiner, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1350 - S1351
[47] Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib
Tang, Kejing
Jiang, Neng
Kuang, Yukun
He, Qiong
Li, Shuhua
Luo, Jiping
Jiang, Wenting
Chen, Yangshan
Sun, Yu
Chen, Lili
Chen, Yanyang
Zhu, Junfeng
Cui, Yongmei
Wan, Han
Ke, Zunfu
THORACIC CANCER, 2019, 10 (02) : 359 - 364
[48] Osimertinib shows promise in treating choroidal metastases and improving vision in EGFR T790M mutation-positive lung adenocarcinoma
Keshwani, K.
Roelofs, K.
Hay, G.
Lewis, R.
Plowman, P.
LUNG CANCER, 2020, 139 : S94 - S94
[49] Monitoring the EGFR T790M mutation in liquid biopsy in patients with lung cancer
Cardos, G.
Motoc, R.
Leonte, D. G. N.
Simion, G.
Gurban, P.
Iordache, F.
Iorga, P.
Apostol, P. P.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 436 - 437
[50] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Zheng, Qiufan
Hong, Shaodong
Huang, Yan
Zhao, Hongyun
Yang, Yunpeng
Hou, Xue
Zhao, Yuanyuan
Ma, Yuxiang
Zhou, Ting
Zhang, Yaxiong
Fang, Wenfeng
Zhang, Li
CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):

← 1 2 3 4 5 →